STOCK TITAN

Iovance Biotherapeutics (IOVA) S-3 Filings

IOVA NASDAQ

Here are the S-3 shelf registrations from Iovance Biotherapeutics, Inc. (IOVA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.

Rhea-AI Summary

Iovance Biotherapeutics, Inc. proposes to offer up to $89,650,167 of common stock via an at-the-market program through Jefferies.

The prospectus supplement states sales may total up to 22,811,747 shares assuming an offering price of $3.93 per share and reports 438,106,537 shares outstanding as of March 31, 2026, rising to up to 460,918,284 shares outstanding after this offering if fully sold. Proceeds are designated to support the commercial launch of Amtagvi®, clinical programs including IOV-LUN-202 and TILVANCE-301, pipeline development and general corporate purposes.